Improvement in liver histology among Asian patients with chronic hepatitis B after long‐term treatment with entecavir

Tong, Myron J.; Kowdley, Kris V.; Pan, Calvin Q.; Hu, Ke; Chang, Ting Tsung; Han, Kwang Hyub; Yoon, Seung Kew; Goodman, Zachary; Beebe, S. P.; Iloeje, Uchenna H.; Tang, Hong

doi:10.1111/liv.12121

Cited by 7 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is possible that the lower virological relapse rates of the aforementioned studies were because of the enrolment of a large proportion of patients with genotype A 11,21 . Published studies have demonstrated that long‐term treatment with NUC significantly improved histological staging in CHB patients, especially with persistent viral suppression by first‐line agents such as entecavir and tenofovir 3,4,22 . However, data are lacking on histological outcomes after the cessation of antiviral monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens

Pan

et al. 2021

Liver International

View full text Add to dashboard Cite

Background & Aims Nucleotides with add‐on interferon treatment (NUC‐IFN) provide significantly higher rates of hepatitis B surface antigen (HBsAg) loss in patients with chronic hepatitis B (CHB). This study aimed to investigate the sustainability of HBsAg loss and the prevention of clinical relapse. Methods Patients with CHB who achieved HBsAg loss and HBV DNA levels <20 IU/ml after IFN or NUC‐IFN therapy were enrolled and followed up for 96 weeks. The primary outcome was HBsAg negativity without viremia at week 96. Secondary outcomes included virological or clinical relapse and predictors of relapse. Results 420 patients were included in intention‐to‐treat analysis with 290 and 130 in the IFN and NUC‐IFN groups respectively. At week 96, the intention‐to‐treat analysis revealed similar outcomes between groups, including HBsAg seroreversion (24.83% vs. 23.08%, P = .70), viremia (16.90% vs 13.08%, P = .32) and clinical relapse (11.38% vs 10.00%, P = .68); the per‐protocol analyses also showed HBsAg seroreversion, viremia and clinical relapse in IFN group (15.50%, 6.59% and 0.39%) did not differ from those in NUC‐IFN group (15.25%, 4.24% and 0.85%, P > .05). These outcomes were similar between patients who received entecavir and those who received telbivudine/lamivudine/adefovir before the combination therapy. In NUC‐IFN‐treated patients, fibrosis regression was observed at week 96. Baseline HBsAb negativity was independent predictors of HBsAg sero‐reversion and recurrence of viremia in IFN treated group. Conclusion NUC‐IFN and IFN therapies are equally effective in achieving sustained functional cure and fibrosis regression. (ClinicalTrials.gov, Number NCT02336399).

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens

Pan

et al. 2021

Liver International

View full text Add to dashboard Cite

show abstract

“…Tedavi ile viral baskılama birlikte histolojik iyileşme de sağlayabilmektedir [4][5][6] . Yapılan çalışmalarda KHB hastalarında antiviral tedavi ile histolojik iyileşme görüldüğü belirlenmiştir [7][8][9][10][11][12] . Nükleoz(t)it analoğu olan tenofovir disoproksil fumarat (DF) ve entekavir ilk basamak tedavide önerilen yüksek genetik bariyere sahip oral antiviral ilaçlardır 5,6 .…”

Section: Introductionunclassified

Tenofovir veya Entekavir Tedavisi Alan Kronik Hepatit B Hastalarında Histolojik Yanıtların Değerlendirilmesi

et al. 2020

View full text Add to dashboard Cite

“…One previous study (Tong et al, 2013) found that an excessively high HBV viral load might inhibit the immunoreactivity and cause immune tolerance; subsequent breaking of this tolerance would induce strong immunoreactions. In the current study, the levels of MIF and IL-17 in the sera of patients in the experimental group began to gradually decrease and the level of IL-10 began to gradually increase during week 4 after Baraclude ® treatment initiation; the levels of anti-inflammatory and proinflammatory cytokines gradually reached a balance, which prevented extensive inflammation and hepatic cell necrosis.…”

Section: Baracludementioning

confidence: 99%

Changes to the migratory inhibitory factor, IL-17, and IL-10 levels in serum from chronic hepatitis B patients and clinical significance following Baraclude® treatment

Yu¹,

Zhang²,

Li³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. This study aimed to determine the relationship between changes in the serum levels of macrophage migratory inhibitory factor (MIF), interleukin (IL) 17, and IL-10 during chronic hepatitis B treatment via Baraclude ® (Bristol-Meyers Squibb). Thirty-six patients with chronic hepatitis B and 24 healthy individuals were selected as the experimental and control groups, respectively, and the serum levels of MIF, IL-17, and IL-10 were measured during the period in which the experimental group was treated with oral Baraclude ® ; meanwhile, the alanine aminotransferase (ALT), hepatitis B virus (HBV) DNA, and HBV marker (M) levels were measured in the experimental group. In the experimental group, the ALT and HBV-DNA levels began to exhibit obvious decreases in week 4, and the MIF and IL-17 levels exhibited obvious increases in week 4 followed by gradual decreases; however, the IL-10 level exhibited an obvious decrease in week 12 and then (2015) increased gradually. These changes were significant when compared with the control group (P < 0.05). In conclusion, Baraclude ® treatment not only actively suppressed HBV but also indirectly balanced the MIF, IL-17, and IL-10 levels and reduced the liver inflammatory response.

show abstract

Improvement in liver histology among Asian patients with chronic hepatitis B after long‐term treatment with entecavir

Cited by 7 publications

References 7 publications

Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens

Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens

Tenofovir veya Entekavir Tedavisi Alan Kronik Hepatit B Hastalarında Histolojik Yanıtların Değerlendirilmesi

Changes to the migratory inhibitory factor, IL-17, and IL-10 levels in serum from chronic hepatitis B patients and clinical significance following Baraclude® treatment

Contact Info

Product

Resources

About